| Opportunity ID: | 332690 | | Opportunity Number: | NOT-CA-21-045 | | Opportunity Title: | Notice of Intent to Publish a Funding Opportunity Announcement for Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) | | Opportunity Category: | Discretionary | | Opportunity Category Explanation: | | | Funding Instrument Type: | Cooperative Agreement | | Category of Funding Activity: | Health | | Category Explanation: | | | CFDA Number(s): | 93.393
93.394
93.395
93.396
93.399 | | Eligible Applicants: | State governments
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses | | Additional Information on Eligibility: | | | Agency Code: | HHS-NIH11 | | Agency Name: | Department of Health and Human Services
National Institutes of Health | | Posted Date: | Apr 06, 2021 | | Last Updated Date: | Apr 06, 2021 | | Estimated Synopsis Post Date: | Jun 18, 2021 | | Fiscal Year: | 2022 | | Award Ceiling: | $1,600,000 | | Award Floor: | | | Estimated Total Program Funding: | $4,800,000 | | Expected Number of Awards: | 3 | | Description: | The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for Radiation Oncology-Biology Integration Network (ROBIN) Centers. The cadre of ROBIN Centers created through this FOA will establish an agile and effective national radiation oncology network infrastructure that collectively address critical hypothesis- based translational research knowledge gaps on the biological basis of responses in cancer patients who undergo radiation treatments. This Notice is being provided to allow potential applicants sufficient time to develop a responsive, multicomponent ROBIN proposal. The FOA is expected to be published in June 2021 with an expected application due date in November 2021. Details of the planned pre-application webinar will be announced in the Guide after publication of the FOA. The FOA will utilize the U54 (Specialized Center-Cooperative Agreements) activity code to support: • Longitudinal collection of clinically annotated research biospecimens, biomarkers, and multimodal data from small cohorts of cancer patients prior to (e.g., baseline), during (e.g., on-treatment), and after radiation therapy. The choice of specific cancer type(s) and characterization plan should be justified based on feasibility, information yield, and likelihood to have impact on significant challenges in radiation oncology to inform the design, and/or health-related outcomes of future clinical trials; • Circumscribed research projects designed to leverage biospecimens, biomarkers, and integrate multiscale, multimodal data obtained from these patient cohorts to test a central hypothesis on mechanistic interactions and biologic consequences of radiation treatment in the specific focus area that thematically defines the Center; • Multidisciplinary workforce development through cross-training and stakeholder engagement in both pre-clinical and translational research to best inform clinical radiation oncology studies, including leveraging data science and informatics approaches. The ROBIN Centers will include human subjects research designated as clinical trials research. The awards we expect to make will support multidimensional, data-dense, small cohort characterization trials of patients receiving standard of care radiation either alone or in a combined modality treatment setting for the cancer(s) of study and will not support clinical trials designed to test for safety or effectiveness of combination treatments. Future clinical trials building on ROBIN Center findings may be supported in a variety of ways, including, but not limited to NCI's Experimental Therapeutics Clinical Trials Network or National Clinical Trials Network. Collectively, data generated through the ROBIN Centers have potential to set the stage for the cancer research community to move towards a new era of personalized radiation oncology where treatment planning may be optimized in novel ways based on an individual patient’s unique biological signatures to reliably predict radiation-combined modality responses, overcome treatment failure, and mitigate normal tissue toxicities. | | Version: | 1 |
|
